HC Wainwright & Co. Reiterates Buy on Rein Therapeutics, Maintains $8 Price Target
Rein Therapeutics, Inc
Rein Therapeutics, Inc RNTX | 0.00 |
HC Wainwright & Co. analyst Brandon Folkes reiterates Rein Therapeutics (NASDAQ:
RNTX) with a Buy and maintains $8 price target.
